Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.61 |
| ▸ | TSHR | P16473 | 3/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.56 |
| ▸ | THRB | P10828 | 1/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | ODC1 | P11926 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | APP | P05067 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tetraethylene Glycol SCHEMBL6422627 | 1.00 | MEN1 (0.61) | MEN1KMT2ATSHRMAPK1THRB | |
| SCHEMBL30230201 | 1.00 | MEN1 (0.61) | MEN1KMT2ATSHRMAPK1THRB | |
| SCHEMBL196866 | 1.00 | MEN1 (0.61) | MEN1KMT2ATSHRMAPK1THRB | |
| Triethylene Glycol SCHEMBL5269020 | 1.00 | MEN1 (0.61) | MEN1KMT2ATSHRMAPK1THRB | |
| Di(Hydroxyethyl)Ether SCHEMBL9686185 | 0.97 | TSHR (0.59) | MEN1KMT2ATSHRMAPK1THRB | |
| Di(Hydroxyethyl)Ether SCHEMBL988734 | 0.97 | TSHR (0.59) | MEN1KMT2ATSHRMAPK1THRB | |
| SCHEMBL197255 | 0.97 | — | — | |
| SCHEMBL3284317 | 0.94 | TSHR (0.56) | MEN1KMT2ATSHRMAPK1THRB | |
| SCHEMBL6859053 | 0.92 | MEN1 (0.58) | MEN1KMT2ATSHRMAPK1THRB | |
| SCHEMBL10035947 | 0.90 | MEN1 (0.60) | MEN1KMT2ATSHRMAPK1THRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120035362-A1 | PHOSPHORAMIDITE DERIVATIVES OF FOLIC ACID | BERRY AND ASSOCIATES, INC. (US) | 2012-02-09 | — | — | US | disclosed |
| WO-2012018729-A1 | PHOSPHORAMIDITE DERIVATIVES OF FOLIC ACID | BERRY AND ASSOCIATES, INC. (US) | 2012-02-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120035362-A1 | PHOSPHORAMIDITE DERIVATIVES OF FOLIC ACID | FOLR1, FOLR2, DHFR | MEN1 147/4885KMT2A 1607/4885TSHR 525/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.